Company Overview - Korro Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on RNA editing for both rare and prevalent diseases [4] - The company utilizes a proprietary RNA editing platform to create a portfolio of differentiated programs aimed at precise and transient single base edits [4] - By editing RNA instead of DNA, Korro aims to enhance the precision and tunability of genetic medicines, potentially leading to improved specificity and long-term tolerability [4] Upcoming Events - Management will participate in several investor conferences, including: - Piper Sandler 36th Annual Healthcare Conference on December 3, 2024, featuring a fireside chat with CEO Ram Aiyar [1] - 7th Annual Evercore ISI HealthCONx Conference on December 4, 2024, with another fireside chat by Dr. Aiyar [2] - Citi's 2024 Global Healthcare Conference on December 5, 2024, with 1x1 investor meetings [2] - Oppenheimer Movers in Rare Disease Summit on December 12, 2024, where Dr. Aiyar will participate in a panel discussion [3] Access to Presentations - Live webcasts of the fireside chats at the Piper Sandler and Evercore conferences will be available on Korro's website, with replays accessible for 30 days post-event [3]
Korro to Participate in Upcoming Investor Conferences